![]() |
|
|
Vol. 54, Issue 6, 968-978, December 1998
Department of Physiology and Biophysics, Mount Sinai School of Medicine of the City University of New York, New York, New York 10029 (A.-O.C., R.O.), and Division of Molecular Medicine, Department of Medicine, Cornell University Medical College and The New York Hospital, New York, New York 10021 (J.H.P., A.J.-P., D.R.N., M.C.G)
| |
Summary |
|---|
|
|
|---|
We have studied the role of a highly conserved tryptophan and other aromatic residues of the thyrotropin-releasing hormone (TRH) receptor (TRH-R) that are predicted by computer modeling to form a hydrophobic cluster between transmembrane helix (TM)5 and TM6. The affinity of a mutant TRH-R, in which Trp279 was substituted by alanine (W279A TRH-R), for most tested agonists was higher than that of wild-type (WT) TRH-R, whereas its affinity for inverse agonists was diminished, suggesting that W279A TRH-R is constitutively active. We found that W279A TRH-R exhibited 3.9-fold more signaling activity than WT TRH-R in the absence of agonist. This increased basal activity was inhibited by the inverse agonist midazolam, confirming that the mutant receptor is constitutively active. Computer-simulated models of the unoccupied WT TRH-R, the TRH-occupied WT TRH-R, and various TRH-R mutants predict that a hydrophobic cluster of residues, including Trp279 (TM6), Tyr282, and Phe199 (TM5), constrains the receptor in an inactive conformation. In support of this model, we found that substitution of Phe199 by alanine or of Tyr282 by alanine or phenylalanine, but not of Tyr200 (by alanine or phenylalanine), resulted in a constitutively active receptor. We propose that a hydrophobic cluster including residues in TM5 and TM6 constrains the TRH-R in an inactive conformation via interhelical interactions. Disruption of these constraints by TRH binding or by mutation leads to changes in the relative positions of TM5 and TM6 and to the formation of an active form of TRH-R.
| |
Introduction |
|---|
|
|
|---|
In
general, native or WT seven-TM GPCRs do not signal in the absence of
agonists. However, several native GPCRs have been found to exhibit
basal or constitutive activity (Arvanitakis et al., 1998
).
For example, the native mouse TRH-R was shown to be active in the
absence of agonist when assayed with a sensitive reporter gene
construct in which a protein kinase C-responsive promoter/enhancer
regulated transcription of a firefly luciferase gene (Jinsi-Parimoo and
Gershengorn, 1997
). The majority of GPCRs that have been found to be
basally active are, however, receptors in which mutations occurred
naturally or were constructed in the laboratory (Lefkowitz et
al., 1993
). Residues whose mutations result in constitutive
activation have been found most often in the third intracellular loop
and TM6 but have also been found in other GPCR domains (Arvanitakis
et al., 1998
). For example, truncation of the
carboxyl-terminal tail of TRH-R results in a constitutively active
receptor (Matus-Leibovitch et al., 1995
). It has been
proposed that activating mutations release the native receptor from an
inactive conformation (Kjelsberg et al., 1992
), and several
groups have suggested that specific interactions among residues in the
helical bundle of GPCRs are involved in constraining native receptors
in inactive conformations (Robinson et al., 1992
; Scheer
et al., 1996
; Groblewski et al., 1997
; Lin
et al., 1997
).
Our computer simulations of the TRH-R predicted that Trp279 (TM6), a
highly conserved residue in GPCRs, is part of a hydrophobic cluster
composed of aromatic residues in TM5 and TM6 (Gershengorn and Osman,
1996
). It has been proposed that conserved residues are critical for
maintaining the common topological features of GPCRs (Baldwin, 1994
)
and their activities (Wess et al., 1993
). Different effects
on receptor function were found, however, when a conserved residue was
mutated in different receptors (Baldwin, 1994
; Van Rhee and Jacobson,
1996
). In this work, we study the roles of the highly conserved
tryptophan in TM6 and of other aromatic residues that form the
hydrophobic cluster between TM5 and TM6 of the TRH-R. We present
experimental evidence that Trp279 and Tyr282 in TM6 and Phe199 in TM5
constrain the TRH-R in an inactive conformation, confirming the
predictions of our computer-generated model.
| |
Materials and Methods |
|---|
|
|
|---|
Computer modeling.
We previously constructed models of the
TRH/WT TRH-R complex using mixed-mode Monte Carlo/stochastic dynamics
simulations, which led to the definition of a transmembrane binding
pocket (Laakkonen et al., 1996
). Simulation of the
binding pocket is in good agreement with experimental findings
(Gershengorn and Osman, 1996
). The extracellular loops of the receptor
were subsequently constructed (Colson et al., 1998
). The
intracellular loops in the WT TRH-R, with and without bound TRH, were
constructed using the protocol described in our previous work.
Materials.
[3H]MeTRH was obtained
from DuPont New England Nuclear.
myo-[3H]Inositol was from Amersham.
TRH was from Calbiochem and MeTRH from Sigma. Dulbecco's modified
Eagle's medium and fetal calf serum were from Collaborative Research.
1-Desaza-TRH and 2-iodo-TRH were generous gifts from L. A. Cohen (National Institutes of Health). Pyr3-TRH and ProMe3-TRH were
generous gifts from T. K. Sawyer (Parke-Davis Pharmaceutical
Research) and C. Y. Bowers (Tulane Medical Center), respectively.
Val2-TRH was from Peninsula. Plasmid containing a protein kinase
C-responsive promoter element fused to the firefly luciferase gene
(AP1-fos-Luc) was a generous gift from P. J. Deutsch
(previously of Cornell University Medical College) (Schadlow et
al., 1992
). All other reagents were from Sigma.
DNA.
Plasmid pCDM8 containing an insert encoding WT mouse
TRH-R (pCDM8mTRHR), as described previously (Perlman et al.,
1995
), was used for transfection. Plasmid pCDM8 containing an insert
encoding W279A TRH-R was constructed as previously described (Perlman
et al., 1995
). The polymerase chain reaction was used to
generate fragments containing the Y200A and F199A mutations, the
fragments were subcloned into plasmid Bluescript encoding WT
TRH-R, and a fragment derived from digestion with XhoI and
NotI was then subcloned into pCDM8mTRHR. Mutations were
confirmed by sequencing using the dideoxy chain termination method.
Cell culture and transfection.
COS-1 cells were maintained
and transiently transfected, using the DEAE-dextran method, as
previously described (Perlman et al., 1995
). In brief, cells
were seeded 1 or 2 days before transfection, at 0.7-1.5 × 106 cells/100-mm dish. After transfection, cells
were maintained in Dulbecco's modified Eagle's medium with 10% fetal
calf serum for 1 day; cells were then harvested and seeded into 12-well
plates, at 100,000 cells/well, in Dulbecco's modified Eagle's medium
with 5% fetal calf serum. AtT-20 cells were maintained and stably
transfected as described (Perlman et al., 1995
).
Receptor binding studies.
One day after reseeding into
12-well plates, competition binding experiments were carried out for 4 hr at 4° with cells in monolayer, in buffer with 2 nM
[3H]MeTRH and unlabeled analogs as described
(Colson et al., 1998
). Ki
values were derived from competition binding experiment data, for which
curves were fitted by nonlinear regression analysis and drawn with the
PRISM program (GraphPad Inc.).
Anti-FLAG M2 chemiluminescence assay in COS-1 cells.
Cells were transfected as described above and seeded (up to 40,000 cells/well) in 96-well plates. On day 2, cells were washed twice with
PBS (1× = 100 mM NaCl, 55 mM sodium
phosphate, pH 7.3) containing 2 mM levels of
Ca2+ and Mg2+ and were
incubated for 1 hr at room temperature with a "blocking solution"
[10% (w/v) dry milk in PBS]. Cells were washed twice and
incubated for 1 hr at room temperature with anti-FLAG M2 antibody (1/300 dilution in PBS with 0.5% bovine serum albumin and 0.1% sodium
azide; Eastman Kodak Co.); cells were then washed twice and incubated
for 1 hr at room temperature with secondary
-galactosidase-conjugated antibody (1/5000 dilution in PBS with
0.5% bovine serum albumin and 0.1% sodium azide). After incubation,
the cells were washed twice, 100 µl of Galacton-Star/Sapphire-II
substrate/enhancer formulation (TROPIX) was added to each well, cells
were incubated for 40 min, and the luminescence was measured for 10 sec.
Luciferase activity assay.
Cells were co-transfected with
plasmid encoding TRH-R (2 µg/ml, unless otherwise indicated) and 2-5
µg/ml plasmid containing AP1-fos-Luc and were incubated in
Dulbecco's modified Eagle's medium containing 10% serum. TRH
stimulation of luciferase gene transcription was measured by adding 10 µM TRH to cells for the last 4 hr of incubation (between
44 and 48 hr). Where indicated, midazolam was added immediately after
transfection. Luciferase activity was assayed as described
(Jinsi-Parimoo and Gershengorn, 1997
), at 48 hr.
| |
Results and Discussion |
|---|
|
|
|---|
To characterize the role of Trp279 in TM6 of TRH-R, Trp279 was replaced by alanine (yielding W279A TRH-R). Competition binding between [3H]MeTRH and a series of unlabeled TRH analogs (all agonists) was measured for WT and W279A TRH-Rs expressed in COS-1 cells (Table 1). The affinity of WT TRH-R for MeTRH was 6-fold higher than that for TRH, and the affinities for 1-desaza-TRH, Val2-TRH, 2-iodo-TRH, Pyr3-TRH, and ProMe3-TRH were 320-, 1200-, 92-, 840-, and 49-fold lower, respectively, than that for TRH. The affinities of W279A TRH-R for MeTRH and 2-iodo-TRH were similar to those of the WT TRH-R; the affinities for TRH, 1-desaza-TRH, Val2-TRH, Pyr3-TRH, and ProMe3-TRH were 6-, 34-, 24-, 7-, and 16-fold higher, respectively, than those of the WT TRH-R. Thus, for five of seven agonists tested, but not for MeTRH or 2-iodo-TRH, the affinities of W279A TRH-R were higher than those of WT TRH-R. These observations are consistent with the idea that W279A TRH-R is more constitutively active than WT TRH-R (see below).
|
A current model of GPCR activation is the allosteric ternary complex
model, which includes an equilibrium between two states of the
unoccupied receptor, namely an inactive state (R) and an active
receptor state (R*) (Samama et al., 1993
). The model
proposes that agonists prefer to bind R* and inverse agonists (i.e.,
agents that inhibit basal activity, also referred to as negative
antagonists) prefer to bind R. It follows from this prediction that
constitutively active mutant GPCRs would bind agonists with higher
affinity than WT receptors and would bind inverse agonists with lower
affinity than WT receptors (Lefkowitz et al., 1993
). This
prediction has been confirmed for many, but not all, GPCR/ligand
systems (Tiberi and Caron, 1994
; Spalding et al., 1995
). The
higher affinity of W279A TRH-R for most agonists tested was consistent
with the idea that W279A TRH-R is constitutively active. To further
characterize the binding profile of W279A TRH-R, binding of competitive
inverse agonists was measured. The affinities of W279A TRH-R for
midazolam and chlordiazepoxide, two benzodiazepine drugs that are
competitive inverse agonists at the TRH-R (Jinsi-Parimoo and
Gershengorn, 1997
) (see below), were 3.4-and 6.5-fold lower,
respectively, than those of WT TRH-R. These data are also consistent
with the idea that W279A TRH-R is more constitutively active than WT
TRH-R.
We previously expressed W279A TRH-Rs in COS-1 cells and measured IP
second messenger formation (Perlman et al., 1995
). TRH stimulated IP formation to the same maximal extent in cells expressing W279A TRH-Rs and cells expressing WT TRH-Rs (see below), but there was
no detectable TRH-independent formation of IPs in COS-1 cells expressing WT or W279A TRH-Rs. We also stably expressed WT and W279A
TRH-Rs in mouse pituitary AtT-20 cells. As with COS-1 cells expressing
WT or W279A TRH-Rs, no stimulation of IP formation was observed in
AtT-20 cells expressing these receptors, in the absence of a TRH
agonist (data not shown).
By using an assay system more sensitive than IP formation, we showed
previously that WT TRH-R is basally active (Jinsi-Parimoo and
Gershengorn, 1997
). A plasmid construct in which a protein kinase
C-responsive promoter/enhancer regulates transcription of a firefly
luciferase gene (AP1-fos-Luc) was coexpressed in COS-1 cells
with WT or W279A TRH-Rs. For WT or W279A TRH-Rs, a maximal level of
luciferase activity was reached after 48 hr. At all time points at
which luciferase activity was detectable, the level was higher in cells
expressing W279A TRH-Rs than in those expressing WT TRH-Rs (data not
shown). The effect of increases in the number of expressed receptors
(produced by varying the amount of plasmid in the transfection
cocktail) on luciferase activity in the absence of agonist was
determined (Fig. 1). The slope of the
relationship between receptor level and basal activity for WT TRH-R was
significantly greater than zero, confirming that the WT TRH-R is
constitutively active. Importantly, the slope of the line describing
the relationship between receptor expression and basal activity for
W279A TRH-R was 3.9 ± 1.0-fold greater than that for WT TRH-R
(nine experiments, p < 0.007, paired one-tailed t test). Therefore, W279A TRH-R is significantly more
constitutively active than is WT TRH-R.
|
The specificity of the basal signaling activity was indicated by the
direct relationship between TRH-R expression and luciferase activity
shown in Fig. 1. To confirm this specificity, incubations in the
presence of the competitive inverse agonist midazolam were performed.
Benzodiazepines do not affect luciferase activity in cells expressing
luciferase without TRH-Rs, and they do not affect TRH-R number under
these conditions (Jinsi-Parimoo and Gershengorn, 1997
). Basal
luciferase activity was completely inhibited by 100 µM
midazolam in cells expressing either WT or W279A TRH-Rs (data not
shown). This confirms our previous finding that midazolam is an inverse
agonist of WT TRH-R (Jinsi-Parimoo and Gershengorn, 1997
). The
IC50 for this effect was 2.1-fold higher for
W279A TRH-R (26 ± 4.5 µM) than for WT TRH-R
(13 ± 3.5 µM), consistent with the observed
difference in binding affinity.
Mixed-mode Monte Carlo/stochastic dynamics simulations performed
previously in our laboratory (Laakkonen et al., 1996
) showed that Trp279 is part of a hydrophobic cluster in the transmembrane bundle of the WT TRH-R. To further examine the behavior of this highly
conserved residue, we conducted long (1-nsec) molecular dynamics
simulations of WT TRH-R with and without bound TRH. In the unoccupied
WT receptor, the
1 torsional angle
(C-C
-C
-C
) of Trp279 calculated from the molecular dynamics
trajectory is, on average, 80 ± 11°. This indicates that the
ring of Trp279 is parallel to the membrane and is involved in stacking
interactions with its neighboring residues, which constrain this region
of the receptor (Fig. 2). In the
TRH-occupied WT receptor, however, the
1 angle
of Trp279 is 152 ± 11°, which results in the plane of the ring
being nearly perpendicular to the membrane, as shown in an
energy-minimized structure obtained over the last 200 psec of the
trajectory presented in Fig. 2. Such a conformational change of Trp279
induced by the binding of TRH in the transmembrane binding pocket
contributes to the release of constraints generated by the stacking
interactions that were present in the unoccupied WT receptor.
|
To gain insight into the mechanism by which constitutive activity
arises, we performed and analyzed a 1-nsec molecular dynamics simulation of W279A TRH-R. Comparison of energy-minimized average structures of W279A and WT TRH-Rs shows significant variations in the
distance between the segments of TM5 and TM6 that are connected to the
putative third intracellular loop (i.e., the distance between the C
atoms of Phe213 and Gln263). This observation led us to analyze
the 1-nsec trajectories of the unoccupied WT, TRH-occupied WT, and
W279A TRH-Rs (2000 structures in each trajectory) to obtain a
distribution of distances between the residues directly attached to
intracellular loop 3 in TM5 and TM6. The results presented in Fig.
3 indicate unimodal distance
distributions for unoccupied and TRH-occupied WT TRH-Rs. This
representation also shows that the average distance between the
intracellular portions of TM5 and TM6 in the unoccupied WT TRH-R is
approximately 3.0 Å shorter than that in the TRH-occupied WT receptor.
If the increased distance between TM5 and TM6 in the TRH-occupied WT
receptor reflects a change that leads to constitutive activity, it is
expected that similar changes in the relative positions of TM5 and TM6
would be observed in the mutant W279A receptor. A similar analysis
performed on W279A TRH-R revealed that the distribution of distances
between the intracellular portions of TM5 and TM6 is bimodal. The peak centered around 15.3 Å represents distances in 65% of the structures in the stable portion of the trajectory (see below). This distribution is comparable to that observed in the TRH-occupied WT receptor (Fig.
3A). Thus, these data are consistent with the idea that an increased
distance between residues at the intracellular borders of TM5 and TM6
is associated with an activated signaling state of the TRH-R.
|
It has been suggested that reorganization of rhodopsin during the
R
R* conformational transition increases the polarity of the
environment of tryptophan residues (Lin and Sakmar, 1996
). If such a
mechanism also occurs in the TRH-R, it would be consistent with
disruption of the closely packed hydrophobic cluster of aromatic residues around Trp279. The hydrophobic cluster surrounding Trp279 is
composed of Phe196, Phe199, Tyr200, Phe275, and Tyr282. Because disruption of this hydrophobic pocket upon mutation of Trp279 to
alanine results in a constitutively active receptor, we hypothesized that mutation of other residues that are part of the hydrophobic cluster could also result in constitutive activity. Among these residues, the side chains of Phe199 and Tyr282 are directed into the
core of the transmembrane bundle, whereas that of Tyr200 is directed to
the outside of the bundle (Fig. 4) and
interacts only loosely with other residues of the hydrophobic pocket.
We therefore predicted that the hydrophobic cluster would be
significantly disrupted upon mutation of Phe199 or Tyr282, leading to a
constitutively active receptor, whereas mutation of Tyr200 would have
little or no effect on the overall conformation of the cluster and
should not lead to constitutive activity. Distance distributions
between residues proximal to intracellular loop 3 in TM5 and TM6 (i.e., the C
atoms of Phe213 and Gln263) were obtained from the 1-nsec molecular dynamics simulations of F199A, Y200A, and Y200F TRH-Rs. The
results presented in Fig. 3B show that the unimodal distribution obtained with F199A TRH-R is similar to that obtained with W279A TRH-R
(Fig. 3A), with an average distance between Phe213 and Gln263 of 14.3 Å, whereas distances in Y200A, Y200F (not shown), and empty WT TRH-Rs
were distributed around 11.5, 11.1, and 12.0 Å, respectively (Fig.
3B). In addition, it is interesting to compare the time of evolution of
this distance in W279A, F199A, and WT TRH-Rs during the simulations
(Fig. 3B, inset). The maximal distance between the
intracellular portions of TM5 and TM6 is reached nearly 200 psec
earlier in F199A TRH-R, compared with W279A TRH-R. These findings
confirm that in our model F199, but not Y200, is important in
constraining TM5 and TM6, and they lead to the predictions that F199A
TRH-R would be more and Y200A TRH-R would be less constitutively active
than W279A TRH-R.
|
To test these predictions, we constructed and characterized F199A and
Y200A TRH-Rs. There was no high affinity binding of [3H]MeTRH to F199A and Y200A TRH-Rs. It is
likely that the markedly lowered affinity of these two receptor mutants
is the result of the effects of these mutations on the TRH binding
pocket (Gershengorn and Osman, 1996
). These findings demonstrate a
problem in the interpretation of findings with mutated receptors,
namely that even site-specific substitutions often affect more than one
receptor function (in this instance, binding of ligand and basal
signaling activity; see below). To measure the expression of receptors
that do not bind [3H]MeTRH with high affinity,
we constructed TRH-Rs containing the FLAG epitope in their amino
termini. Fig. 5 illustrates that FLAG epitope-tagged and untagged TRH-Rs are stimulated by TRH to produce IPs
to the same maximal extents. Using an antibody-based chemiluminescence assay, we found that WT, W279A, F199A, and Y200A TRH-Rs were expressed to similar levels in COS-1 cells (Fig.
6). We were, therefore, able to compare
the intrinsic basal signaling activities of these TRH-Rs under our
standard conditions. Using the luciferase assay (see above), we found
that F199A TRH-R exhibited a higher basal signaling activity than did
W279A TRH-R, whereas Y200A TRH-R was only as active as WT TRH-R (Figs.
6 and 7B). As with W279A TRH-R, there was
no effect on basal IP formation in COS-1 cells expressing either of
these receptor mutants, but TRH caused dose-dependent stimulation of IP
formation in cells expressing F199A and Y200A TRH-Rs. As predicted from
the lack of high affinity binding, the potencies for TRH-stimulated
signaling by F199A and Y200A TRH-Rs were decreased, compared with WT
and W279A TRH-Rs; the EC50 values were 210 nM (95% confidence interval, 110-390 nM) for
F199A TRH-R and 7.2 nM (2.4-22 nM) for Y200A
TRH-R (data not shown), compared with 1.1 nM for WT and
W279A TRH-Rs (Perlman et al., 1995
). For all four TRH-Rs
tested, the maximal levels of TRH stimulation of IP formation varied
directly with the amount of plasmid included in the transfection
cocktail (Fig. 7A), consistent with the idea that more receptors were
expressed in transfections with larger amounts of plasmid. These data
are consistent with our model.
|
|
|
Our model suggests that another hydrophobic residue, Tyr282, which is positioned above W279, is also part of the cluster and is directed into the core of the transmembrane bundle (Fig. 4). Tyr282 is hydrogen-bonded to Tyr192 in the unoccupied receptor and is in close proximity to W279. In the occupied receptor, the hydrogen bond to Tyr192 is replaced by an interaction with the backbone of TRH, and the aromatic ring of Tyr282 stacks on the histidine side chain of TRH. It appears that Tyr282 constrains the unoccupied receptor in its inactive form. It is therefore anticipated that mutation of Y282 should relieve the constraint and generate a constitutively active receptor. A 1-nsec simulation of the Y282A TRH-R mutant shows a bimodal distribution of the distances between the intracellular portions of TM5 and TM6 (Fig. 3B). The peak centered around 13.2 Å represents distances calculated in 70% of the structures. It corresponds to a distance located halfway between the distances calculated in the unoccupied receptor and the F199A and W279A receptors, which suggests that constitutive activity should be observed with the mutant receptor.
To further test the predictions of our model, we studied the basal
signaling activities of Y282A and Y282F TRH-Rs. Y282A and Y282F TRH-Rs
exhibited basal signaling activities that were higher than that of WT
TRH-R (1.7 ± 0.26- and 1.9 ± 0.25-fold higher than that of
WT TRH-R, respectively) (Fig. 8) but were
not as high as those of W279A or F199A TRH-Rs. We also investigated
whether there was any effect of the substitution of these hydrophobic residues on TRH induction of gene transcription (Fig. 8). The absolute
levels of maximal induction by TRH were similar in cells expressing all
of these mutant TRH-Rs. When the induction produced by TRH was analyzed
as fold increases above basal activity, then the cells expressing F199A
and W279A TRH-Rs, which are the most basally active receptors,
exhibited lowered fold induction, compared with cells expressing the
other TRH-Rs. This may be because the cells cannot increase
transcription of the luciferase gene above this apparent maximal level
or because the more basally active receptors cause the cells to be
desensitized to TRH. The former seems more likely, because levels of
TRH-stimulated signaling by F199A and W279A TRH-Rs, measured as IP
formation, were similar in cells expressing all of these TRH-Rs (Figs.
5 and 7) (Perlman et al., 1996
). Therefore, our model
correctly predicted which of four mutations of proximate aromatic amino
acid residues in a hydrophobic pocket of TRH-R would lead to
constitutive activity and which would not.
|
Our computer-generated model predicts that significant movement occurs
in the region in TM5 proximal to the third intracellular loop (see
above) but that much less motion is observed at the extracellular end
of the helix (Fig. 9). This suggests that
the hydrophobic cluster described above constrains WT TRH-R primarily at the extracellular side of the TM. Disruption of this hydrophobic pocket by mutation of residues within the cluster, or by binding of TRH
(Fig. 1), results in receptor activation. A similar observation regarding constraint of helices 5 and 6 by a hydrophobic cluster of
residues has been made in studies of the lutropin/choriogonadotropin receptor (Lin et al., 1997
). In that case, the cluster
appears to be within the intracellular part of the helices, rather than nearer the extracellular region, as in TRH-R. However, the exact boundaries of the helices in GPCRs are not known and the hydrophobic cluster may be comparable in the two receptors. Nevertheless, it
appears that different GPCRs use interactions between hydrophobic residues in helices 5 and 6 to constrain the receptor in an inactive state. Loss of a constraint present in native GPCRs has been proposed as a general mechanism of GPCR activation (Lefkowitz et al.,
1993
). A result of loss of a constraint may be increased mobility of domains within the receptor protein, and several reports have presented
evidence that increased intramolecular mobility is associated with GPCR
activation. For example, studies with spin-labeled rhodopsin are
consistent with the idea that TM5 and the intracellular loop that
connects it to TM6 are more mobile upon photoactivation (Altenbach et al., 1996
; Farrens et al., 1996
), and studies
of a fluorescently labeled, constitutively active,
1B-adrenergic receptor are consistent with it
exhibiting increased mobility, compared with the WT receptor (Gether
et al., 1997
; Javitch et al., 1998
). Because a
tryptophan in TM6 corresponding to Trp279 in TRH-R is conserved among
the rhodopsin/
-adrenergic receptor subfamily of GPCRs (Probst
et al., 1992
), it is important to determine whether this
tryptophan plays a general role in maintaining the inactive state.
However, replacement of the conserved tryptophan by phenylalanine did
not result in a basally active m3 muscarinic receptor, possibly because phenylalanine may form an aromatic interaction like tryptophan and
thereby effectively maintain an inactive state (Wess et al., 1993
). Replacement of tryptophan by alanine in the
AT1A angiotensin receptor resulted in lowered
agonist affinity and no change in affinity for antagonists, changes
that are not suggestive of constitutive activity, but basal activity
was not directly measured (Yamano et al., 1995
). Thus, a
role for this conserved tryptophan in constraining other GPCRs in an
inactive state has not been shown.
|
The tryptophan in TM6 has been shown to be important in other aspects
of GPCR structure and function. In the m3 muscarinic receptor, its
replacement by phenylalanine led to decreased maximal activity of
approximately 70% of WT receptor activity (Wess et al.,
1993
). In the AT1A angiotensin receptor, it has
been proposed that this tryptophan is involved in ligand binding,
because it may stabilize an ionic bridge between a lysine in TM5
(adjacent to the position homologous to that of Phe196 in TM5 of TRH-R) and the terminal carboxylate of angiotensin II (Yamano et
al., 1995
). In rhodopsin, the tryptophan in TM6 was shown to
interact strongly with retinal, and it was proposed to be critical for activation (Nakayama and Khorana, 1991
; Lin and Sakmar, 1996
). Thus,
although the tryptophan in TM6 is important, its predominant role, as
determined thus far, appears to differ among members of the
rhodopsin/
-adrenergic receptor subfamily of GPCRs. It may be that
this tryptophan is conserved for a common critical reason that has not
yet been determined or that its role has changed in different GPCRs
during evolution.
Other conserved residues have been proposed to be critical for
maintaining the inactive state of GPCRs. In the
-factor receptor, which does not contain the conserved tryptophan in TM6, mutation of a
nearby conserved proline resulted in constitutive activity (Konopka
et al., 1996
). The negative charge of an aspartate in TM2 of
the bradykinin receptor was found to be necessary to prevent basal
activation (Quitterer et al., 1996
). An arginine of the Glu(Asp)-Arg-Tyr sequence at the bottom of TM3 in the
1B-adrenergic receptor has been proposed to
interact with a highly conserved transmembrane polar pocket, consisting
of an asparagine in TM1, an aspartate in TM2, an asparagine in TM7, and
a tyrosine in TM7, to constrain the receptor in an inactive
conformation (Scheer et al., 1996
). Evidence for
interactions among an asparagine in TM1, an aspartate in TM2, and an
asparagine in TM7 in TRH-R has also been presented (Perlman et
al., 1997
). It is noteworthy, however, that mutation of the same
conserved residue in the
1B-adrenergic receptor and TRH-R causes different effects. For example, replacement of asparagine in TM1 by alanine in the
1B-adrenergic receptor leads to a GPCR that is
basally active and can be activated by agonist to the same level as the
WT receptor (Scheer et al., 1996
), whereas the mutant TRH-R
with substitution of asparagine in TM1 by alanine exhibits no increase
in basal activity and maximal signaling of only 37% of WT TRH-R levels
(Perlman et al., 1997
). Therefore, a number of conserved
residues appear to be involved in intramolecular interactions that
constrain receptors of the rhodopsin/
-adrenergic subfamily of GPCRs
in an inactive state.
Our model predicts that there is increased motion in the intracellular
portion of TM5 in the TRH-R, compared with the extracellular end.
Pro203 in TM5, which is highly conserved in the
rhodopsin/
-adrenergic receptor subfamily, appears to cause formation
of a kink in the helix that could allow for the differences in motion
at the two ends of the same helix. We have calculated the extent of the
kink in TM5 in our model as the angle between two helical axes defined by the portions of the helix before and after the kink. This algorithm was implemented in the program CHARMM (Brooks et al., 1983
).
The axis before the kink is defined by the C
atoms of residues
190-203 and the one after the kink by the C
atoms of residues
203-213. The results obtained from the analysis performed over the
last 500 psec of the trajectories show that in WT TRH-R the average kink angle is 153 ± 4°, whereas in the TRH-occupied receptor
the value is 162 ± 7°. A similar analysis of the mutant
receptors shows that in the Y200A TRH-R the kink angle is 146 ± 4°, whereas in the more constitutively active receptors Y282A TRH-R,
F199A TRH-R, and W279A TRH-R the values are 154 ± 4°, 157 ± 3°, and 165 ± 3°, respectively. A statistical analysis
(t test) shows that the values for the TRH-occupied F199A
and W279A TRH-Rs are significantly different (p < 0.05) from those for WT and Y200A TRH-Rs. Fig. 9B presents the kink
angles measured in the average structures that were energy-minimized
over the last 200 psec of the trajectories; these findings suggest
that, in the occupied and constitutively active receptors, TM5 has a
tendency to straighten out and reduce the proline kink.
It has been suggested that, because the kink region does not have a
periodicity of 3.6 amino acids/turn, a twisting of the faces occurs
after the proline kink, relative to a straight helix (Ballesteros and
Weinstein, 1992
; Sankararamakrishnan and Vishveshwara, 1992
). If the TM
proline residues can be thought of as local helical hinge points
allowing two separate rigid bodies to be functionally separated, as
suggested by Woolf (1997)
, then twisting of the two separate domains
around the proline residue is also likely to occur. In this work, we
observed that, in the average structures, the intracellular part of TM5
appears to undergo a more significant rotation in the constitutively
active F199A and W279A receptors than in the inactive Y200A and Y200F
receptors, which leads us to suggest that straightening of the helical
kink is associated with a significant twist of the intracellular
portion of TM5.
Therefore, our results suggest that a release of the constraint imposed
by Trp279 or Phe199 near the top of TM6 and TM5 results in increased
distances between the intracellular portions of TM5 and TM6, as well as
a conformational change transduced through TM5 to intracellular loop 3, which is known to be critical for activation of the TRH-R (Nussenzveig
et al., 1993
). These changes in the intracellular portion
are accomplished by the unkinking of the proline kink in the middle of
the helix and by a conformational change that can be represented as a
face-twisting of the lower portion of TM5.
In conclusion, a model of the TRH-R was presented that predicts that
Trp279 and Phe199 belong to the same hydrophobic cluster and are
important for constraining the TRH-R in an inactive conformation. Experimental support for the model was obtained by showing that replacement of Phe199 and Trp279 by alanine results in constitutively active receptors with greater basal activity, compared with WT TRH-R.
We propose that Trp279 in TM6 and at least Phe199 in TM5 hold the TRH-R
in an inactive conformation by participating in interhelical
interactions within a hydrophobic cluster of residues. Upon disruption
of this hydrophobic pocket, either by TRH occupancy or by substitution
of Trp279 or Phe199 with alanine, there is a release of these
constraining interactions that leads to a change in the position and
conformation of TM5. This change can be transmitted to intracellular
loop 3, which has been shown to be important in TRH-R activation
(Nussenzveig et al., 1993
). We think that these changes are
involved in TRH-R activation and may be part of a general mechanism of
GPCR activation.
| |
Footnotes |
|---|
Received May 8, 1998; Accepted August 26, 1998
This work was supported by National Research Service Award DK09647 (A.-O.C.), National Institutes of Health Physician Scientist Award DK02101 (J.H.P.), and National Institutes of Health Grant DK43036 (M.C.G., R.O.). A.-O.C. and J.H.P. contributed equally to this work.
Send reprint requests to: Dr. Marvin C. Gershengorn, Cornell University Medical College, 1300 York Avenue, Room A328, New York, NY 10021. E-mail: mcgersh{at}mail.med.cornell.edu
| |
Abbreviations |
|---|
WT, wild-type; GPCR, G protein-coupled receptor; TRH, thyrotropin-releasing hormone; TRH-R, thyrotropin-releasing hormone receptor; TM, transmembrane helix; IP, inositol phosphate; MeTRH, [N-t-methylhistidine]thyrotropin-releasing hormone; 1-desaza-TRH, [desazapyro-Glu]thyrotropin-releasing hormone [Na-[(1R)-3-oxocyclopentanecarbonyl]-L-histidyl-L-prolineamide]; bp, base pair(s); PBS, phosphate-buffered saline.
| |
References |
|---|
|
|
|---|
1B-adrenergic receptor by all amino acid substitutions at a single site: evidence for a region which constrains receptor activation.
J Biol Chem
267:
1430-1433
-factor receptor.
Proc Natl Acad Sci USA
93:
6764-6769
2-adrenergic receptor: extending the ternary complex model.
J Biol Chem
268:
4625-4636
1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation.
EMBO (Eur Mol Biol Organ) J
15:
3566-3578[Medline].This article has been cited by other articles:
![]() |
C.-R. Chen, S. M. McLachlan, and B. Rapoport Suppression of Thyrotropin Receptor Constitutive Activity by a Monoclonal Antibody with Inverse Agonist Activity Endocrinology, May 1, 2007; 148(5): 2375 - 2382. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Foucaud, I. G. Tikhonova, I. Langer, C. Escrieut, M. Dufresne, C. Seva, B. Maigret, and D. Fourmy Partial Agonism, Neutral Antagonism, and Inverse Agonism at the Human Wild-Type and Constitutively Active Cholecystokinin-2 Receptors Mol. Pharmacol., March 1, 2006; 69(3): 680 - 690. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Lu, W. Huang, S. Worthington, P. Drabik, R. Osman, and M. C. Gershengorn A Model of Inverse Agonist Action at Thyrotropin-Releasing Hormone Receptor Type 1: Role of a Conserved Tryptophan in Helix 6 Mol. Pharmacol., November 1, 2004; 66(5): 1192 - 1200. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Beukers, J. van Oppenraaij, P. P. W. van der Hoorn, C. C. Blad, H. d. Dulk, J. Brouwer, and A. P. IJzerman Random Mutagenesis of the Human Adenosine A2B Receptor Followed by Growth Selection in Yeast. Identification of Constitutively Active and Gain of Function Mutations Mol. Pharmacol., March 1, 2004; 65(3): 702 - 710. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Govaerts, A. Bondue, J.-Y. Springael, M. Olivella, X. Deupi, E. Le Poul, S. J. Wodak, M. Parmentier, L. Pardo, and C. Blanpain Activation of CCR5 by Chemokines Involves an Aromatic Cluster between Transmembrane Helices 2 and 3 J. Biol. Chem., January 10, 2003; 278(3): 1892 - 1903. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sun and M. C. Gershengorn Correlation between Basal Signaling and Internalization of Thyrotropin-Releasing Hormone Receptors: Evidence for Involvement of Similar Receptor Conformations Endocrinology, August 1, 2002; 143(8): 2886 - 2892. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Gershengorn and R. Osman Minireview: Insights into G Protein-Coupled Receptor Function Using Molecular Models Endocrinology, January 1, 2001; 142(1): 2 - 10. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. H. Song, C.-A. Slowey, D. P. Hurst, and P. H. Reggio The Difference between the CB1 and CB2 Cannabinoid Receptors at Position 5.46 Is Crucial for the Selectivity of WIN55212-2 for CB2 Mol. Pharmacol., October 1, 1999; 56(4): 834 - 840. [Abstract] [Full Text] |
||||
![]() |